Online inquiry

IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7782MR)

This product GTTS-WQ7782MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MMP9 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_004994.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4318
UniProt ID P14780
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7782MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4137MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ5888MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ5918MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ4404MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ7052MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ10569MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ15711MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ12780MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW